STUDY TITLE
An exploratory study of Venetoclax in combination with Bortezomib-Cyclophosphamide-Dexamethasone (VCD) induction therapy in newly diagnosed transplant eligible (NDTE MM) multiple myeloma with proteomic correlative studies
STUDY DESIGN
Multicentre, single arm, open label trial
CORRELATIVE STUDIES
Blood and bone marrow samples will be collected as part of the trial, and studied for molecular biomarkers and disease response
TRIAL PRINCIPAL INVESTIGATOR
Professor Andrew Spencer
TIME FRAME
2018 – 2021
PARTICIPANTS
Newly diagnosed patients with multiple myeloma, who will receive an Autologous Stem Cell Transplant (ASCT)
TOTAL ENROLMENT
17
STATUS
Closed to Recruitment
SITE LOCATIONS
-
Alfred Hospital, VIC
-
Austin Hospital, VIC
-
St George Hospital, NSW